2023/24 review: A message from Lynne Berry, Chair

In recent years, improved technology and significant changes to our sectors have presented challenges and opportunities. This has resulted in us adapting our regulatory approach to ensure they do not become barriers to the use of human tissue or innovation. We have since applied our learning to help shape our approach.

In 2023/24, we set ourselves an ambitious agenda and I am proud to say we delivered real, tangible impact. We drove forward efficiencies in our regulatory approach by taking a more proportionate stance using new and updated regulatory tools. We also developed how we engage with our licensed establishments and key stakeholders to better understand their experiences and gain insights. This intel helped identify and inform our priorities, respond to the threat of human trafficking for organ removal, and support the post-mortem sector to improve management of the deceased.

This review takes a thematic approach to demonstrating a number of our achievements over the last business year. Our work shows we used our expertise and intel to guide, advise and collaborate. It also shows that we support our licensed establishments, including frontline NHS services, when delivering our regulatory work. This brought about change in our sectors and the wider system, and provides reassurance to the public that we are regulating with expert oversight.

Our values underpin our work. They are the principles that ground how we operate as an organisation and how we interact with one another, our stakeholders and license establishments. By taking a values-led approach, we are committed to work together and with transparency. It puts us in a strong position to oversee our sectors, address changes or inefficiencies and implement new ways of working.

I would like to thank everyone who worked with us last year. We will continue to work collaboratively to deliver on our mission to be an excellent regulator that sustains public and professional confidence, today and in the future.

Lynne Berry CBE

Chair, Human Tissue Authority